Expression of apoptosis-suppressing gene bcl-2 in human carotid body tumours

Journal of Pathology

Volumn 183, Issue 2, 1997, Pages 218-221

  Wang, Da Gong ^a,c   Johnston, Colin F ^a   Barros D'sa, Aires A B ^b   Buchanan, Keith D ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c WELLCOME RESEARCH LABORATORIES   (United Kingdom)

Author keywords

Apoptosis; Bcl 2; Carotid body tumour; Pathogenesis

Indexed keywords

PROTEIN BCL 2;

ADOLESCENT; ADULT; ALTITUDE; APOPTOSIS; ARTICLE; CAROTID BODY TUMOR; CLINICAL ARTICLE; FAMILIAL DISEASE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; ONCOGENE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CAROTID BODY TUMOR; FEMALE; GENE EXPRESSION; GENES, BCL-2; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, NEOPLASM;

EID: 0030806170     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199710)183:2<218::AID-PATH910>3.0.CO;2-J     Document Type: Article

References (30)

1. Pacheco-Ojeda L, Durango E, Rodriguez C, Vivar N. Carotid body tumours at high altitudes; Quito, Ecuador, 1987. World J Surg 1988; 31: 113-118.
2. Parry DM, Li FP, Stong LC, et al. Carotid body tumours in humans: genetics and epidemiology. J Natl Cancer Inst 1982; 68: 573-578.
3. Lack EE, Cubilla AL, Woodruff JM. Paragangliomas of the head and neck region: a pathologic study of tumours from 71 patients. Hum Pathol 1979; 10: 191-218.
4. Dickinson PH, Griffin SN, Guy AJ, McNeill IF. Carotid body tumours: a 30 years experience. Br J Surg 1986; 73: 14-16.
5. Arias-Stella J. Human carotid body at high altitude (Abstract). J Pathol 1969; 55: 82.
6. Edwards C, Heath D, Harris P, Castillo Y, Kruger H, Arias-Stella J. The carotid body in animals at high altitude. J Pathol 1971; 104: 231-279.
7. Saldana MJ, Salem LE, Traveza R. High altitude hypoxia and chemdectomas. Hum Pathol 1973; 4: 251-263.
8. Williams GT, Smith CA, Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993; 74: 777-779.
9. McDonnell TJ. Cell division versus cell death: a functional model of multistep neoplasia. Mol Carcinog 1993; 8: 209-213.
10. Wang DG, Johnston CF, Anderson N, Sloan JM, Buchanan KD. Over-expression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis. J Pathol 1995; 175: 397-401.
11. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
12. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nunez G. Expression of the apoptosis-suppressing protein bcl-2 in neuroblastoma is associated with unfavourable histology and N-myc amplification. Am J Pathol 1993; 143: 1543-1550.
13. Reed JC, Meister L, Tanaka S, et al. Differential expression of bcl-2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 1991; 51: 6529-6538.
14. Ramani P, Lu QL. Expression of bcl-2 gene product in neuroblastoma. J Pathol 1994; 172: 273-278.
15. Viale G, Roncalli M, Grimelius L, et al. Prognostic value of bcl-2 in immunoreactivity in medullary thyroid carcinoma. Hum Pathol 1995; 26: 945-950.
16. Wang WL, Johansson H, Bergholm U, Wilander E, Grimelius L. Apoptosis and expression of the protooncogene bcl-2 and p53 and the proliferation factor Ki-67 in human medullary thyroid carcinoma. Endocrine Pathol 1996; 7: 37-45.
17. Jiang SX, Sato Y, Kuwao S, Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1996; 177: 135-138.
18. Jiang SX, Kameya T, Sato Y, Yanase N, Yoshimura H, Kadama T. bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am J Pathol 1996; 148: 837-846.
19. Zhong LT, Sarafian T, Kane DJ, et al. bcl-2 inhibits death of central neural cells induced by multiple agents. Proc Natl Acad Sci USA 1993; 90: 4533-4537.
20. Buchanan KD, Johnston CF, O'Hare MMT, et al. Neuroendocrine tumours: a European view. Am J Med 1986; 81: 14-22.
21. Wang DG, Johnston CF, Atkinson AB, Heaney AP, Mirakhur M, Buchanan KD. Expression of bcl-2 oncoprotein in pituitary tumours: comparison with c-myc. J Clin Pathol 1996; 49: 759-797.
22. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83: 5214-5218.
23. Mah SP, Zhong LT, Liu Y, Roghani A, Edwards RH, Bredesen DE. The protooncogene bcl-2 inhibits apoptosis in PC12 cells. J Neurochem 1993; 60: 1183-1186.
24. Lindenboim L, Haviv R, Stein R. Inhibition of drug-induced apoptosis by survival factors in PC12 cells. J Neurochem 1995; 64: 1054-1063.
25. Martin DP, Schmidt RE, Distefano PS, Lowry OH, Carter JG, Johnson EM. Inhibitors of protein synthesis prevent neuronal death caused by nerve growth factor deprivation. J Cell Biol 1988; 196: 829-844.
26. Vaux DL, Cory S, Adama JM. bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
27. McDonnell TJ, Nunez G, Platt FM, et al. Deregulated Bcl-2-lg transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mol Cell Biol 1990; 10: 1901-1907.
28. McDonnell TJ, Korsmeyer SL. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991; 349: 254-256.
29. Korsmeyer SJ. bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-886.
30. McDonnell TJ, Deane N, Platt FM, et al. bcl-2 immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88.